Cited by 75Psoriasis: Treatment and PathogenesisT-cell and B-cell ImmunologyRheumatoid Arthritis Research and Therapies

The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.

Th17 cell pathogenicity in autoimmune disease

Open access
Park, Eunchong, Ciofani, Maria·2025·Experimental & Molecular Medicine

Abstract

T helper 17 (Th17) cells have been implicated in numerous inflammatory autoimmune diseases. Clinical benefits from targeting Th17 cell-related cytokines, such as IL-17 and IL-23, highlight how knowledge of Th17 cell development and effector function can be translated into treatments for inflammatory disease. Here we discuss the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease and psoriasis, with emphasis on the cytokines, transcriptional regulators and metabolites that influence Th17 cell differentiation and pathogenicity. Moreover, we address how intestinal environments and physiological responses affect Th17 cells in autoimmune diseases. We also examine current and emerging therapeutic strategies aimed at regulating Th17 cell-driven inflammation to mitigate autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-025-01535-9

Cites

281 of 281 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Therapeutic approaches targeting Th17 cell-driven inflammation. a SMIs can target JAK isoforms or transcription factors such as RORγt and RORα to suppress Th17 cells. ADC can promote the target-specific delivery of SMIs. b Blockade of cytokines or cytokine receptors using antibodies or peptides can inhibit Th17 cell-mediated inflammation. c Inhibitory antibodies targeting integrins or adhesion molecules can inhibit the infiltration of Th17 cells into the site of inflammation. d CAR-T cells can directly kill pathogenic cells in Th17 cell-driven inflammation. CAR-Treg cells can suppress inflammation driven by Th17 cells.
Fig. 1 Therapeutic approaches targeting Th17 cell-driven inflammation. a SMIs can target JAK isoforms or transcription factors such as RORγt and RORα to suppress Th17 cells. ADC can promote the target-specific delivery of SMIs. b Blockade of cytokines or cytokine receptors using antibodies or peptides can inhibit Th17 cell-mediated inflammation. c Inhibitory antibodies targeting integrins or adhesion molecules can inhibit the infiltration of Th17 cells into the site of inflammation. d CAR-T cells can directly kill pathogenic cells in Th17 cell-driven inflammation. CAR-Treg cells can suppress inflammation driven by Th17 cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 280 references

Research works printed but not linked: 1

  1. Thakore, P. I. et al. BACH2 regulates diversification of regulatory and proinflammatory chromatin states in TH17 cells. Nat. Immunol. 25, 1395–1410 (2024). · DOI · Paper page

Cited by

Sorted by citations

See all 75

Metadata

Authors
Park, E., & Ciofani, M.
Affiliations
  • AstraZeneca (United States) (US)
  • Duke University (US)
Corresponding author
Ciofani, Maria
Venue
Experimental & Molecular Medicine
Published
2025-09-01
Volume
57
Issue
9
Pages
1913-1927
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W4413865457
Cited by
75
References
280
Citations by year
2026: 70 · 2025: 5
FWCI
6.71
Type
journal article
Language
en
Open access
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI156186)
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM115474)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Keywords
Th17 cells, autoimmune disease, IL-17, IL-23, Th17 cell differentiation, multiple sclerosis, inflammatory bowel disease, psoriasis, transcription factors, metabolites, intestinal environment, anti-inflammatory therapy
MeSH terms
Animals, Autoimmune Diseases, Cell Differentiation, Disease Susceptibility, Humans, Cytokines, Th17 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review